Abiopharma

News list

Director Zheng Jie 🟢 acquired 165.7K shares (2 derivative) of H World Group Ltd (HTHT) Transaction Date: Mar 31, 2026 | Filing ID: 038209

Full text

News bot April 1, 2026, 11:41 a.m.
🔍 Zheng Jie (Director)

Company: H World Group Ltd (HTHT)

Report Date: 2026-03-31
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 2
- Holdings reported: 0
- Total shares acquired: 165,740
Detailed Transactions and Holdings:
- Acquired 157,740 shares of Restricted Share Units (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 236,850.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
- Acquired 8,000 shares of Restricted Share Units (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 244,850.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
Footnotes:
- F1: Each restricted share unit represents the right to receive one ordinary share.
- F2: These performance-based restricted share units were granted on March 31, 2026 and are scheduled to vest in five installments, with 50% on the second anniversary of the vesting start date and 1/8 on the last day of each succeeding six-month period, ending on January 1, 2029.
- F3: These performance-based restricted share units were granted on March 31, 2026 and are scheduled to vest in five installments, with 50% on the second anniversary of the vesting start date and 1/8 on the last day of each succeeding six-month period, ending on January 13, 2029.